Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × vandetanib × Clear all

Phase

Phase 2 20 Phase 1 18 Phase NA 1 Phase 1/2 1

Status

Sponsor Class

NIH 3 INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Gliosarcoma 1 Glioblastoma 1

Interventions

Cyclophosphamide 220 Radiotherapy 157 Carboplatin 136 pembrolizumab 134 Nivolumab 127 Gemcitabine 126 Paclitaxel 121 Cisplatin 105 fludarabine 102 Dexamethasone 102 Lenalidomide 93 Rituximab 90 Docetaxel 90 Bevacizumab 86 Capecitabine 85 Temozolomide 84 fludarabine phosphate 81 Cytarabine 79 Oxaliplatin 76 Irinotecan 70 Etoposide 70 Filgrastim 69 Melphalan 65 Doxorubicin 65 venetoclax 64 Peripheral Blood Stem Cell Transplantation 63 Fluorouracil 61 Everolimus 60 Radiosurgery 57 durvalumab 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00441142 2019-03-05

Zactima

Dana-Farber Cancer Institute

Phase 1/2 Completed

119 enrolled 15 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡